Our chips were developed with FDA regulatory requirement in mind: we pioneered a new chip substrate material, PUMA, which is a USP-Class VI medical grade material. This work was featured as the cover of Lab on a Chip in April of 2009.
We have developed a system to reliably isolate CTCs from blood. Our system consists of a capital equipment and consumables: a chemical kit for tagging cancer cells, a disposable biochip that isolates CTCs from blood, and a microscopy system with eDAR technology for automating the sorting process and imaging the cells. In our recent clinical tests involving breast cancer patients we have recovered more than 100x cancer cells than a FDA-approved test.
In Asia, there are five main countries, Singapore, Korea, China, Japan, and Taiwan developing their advantages in Biotech. Singapore build up the two Biotech Research Park, Tuas Biomedical Park and Biopolis, with tax-free policies and well facilities to attract GSK, Merck, Novartis, Pfizer to move into these regions. The big pharma provides the experts and talents and do the education for the local scientist. Korea’s biotech are highly-supporting from their government fund. Their government fund announce to give Samsung $3 Billion to develop the cancer new drug, and give LG Life Science $1.5 Billion to discover the stem cell therapeutics. In China, they don’t have a very advance technology, but they have advantage on the a big domestic market and low cost labor. In Japan, they have a very great basic and clinical research, and closed market for the foreign competitiors. In Taiwan, we have the best supply chain to do the OEM and ODM business in IT industry. In addition, we have more than 8,000 graduates in the bio-fields. However, the economic environment and well-constructed infrastructure are the key issues for Biotech Industry Success.
20110706 Private Equity Summit Allen Lin
Exploring the Business Opportunities in Taiwan- Perspectives on Biotech Investment Allen Lin ( 林群倫 ) YFY Biotech Management Company/ Taiwan Global Biofund July 6, 2011 4F, 51, Sec 2, Chung Ching South Rd. Taipei, Taiwan, R.O.C. Email: [email_address]
Outline <ul><li>Who are We? </li></ul><ul><li>Capital Market in Taiwan’s Biotech Industry </li></ul><ul><li>The Trends in Biotech Investment </li></ul><ul><li>Cases in Biotech Industry </li></ul><ul><li>Future Perspectives </li></ul>
About Us <ul><li>Established in Nov 2003, YFY biotech Management Company is one of the leading biotechnology investment companies in Taiwan. </li></ul><ul><li>We focus on companies involved in biotechnology, pharmaceuticals, diagnostics, medical devices, medical services, medical informatics and related medical technologies with a potential to become an industrial leader. </li></ul><ul><li>We currently manage Taiwan Global Biofund (TGB), with a fund size of US$75 million and SME fund with US$45 million. </li></ul>
Portfolio Companies Company name ： TaiMed Biologics http://www.taimedbiologics.com.tw/ Company name ： NeuroSky Inc. Website ： http://www.neurosky.com/ Company name ： CMS Website ： http://www.cmsholdings.com/ Company name ： Medigen Biology Cor. http://www.medigen.com.tw/
<ul><li>The Trends in Biotech </li></ul><ul><li>Investment </li></ul>
Life Science Investment Thesis Source ： Burrill&Co. 2008 Report Building sustainable businesses K Biopharmaceuticals Seeds Food ingredients Bio Fuels Biomaterials Bio Processing Tools Agriculture Addressing major market needs Therapeutics Traits Diagnostics Wellness Enhancers Medical devices Services Human Health Care “ Sustain & Nourish the world” FEED THE WORLD FUEL THE WORLD HEAL THE WORLD
Historical Trends in Biotech Fields Source: National Center for Biotechnology Information, PubMed Proteomics RNAi Gene therapy
New Trends in Biogenerics Lonza Teva Imclone Eli Lilly MedImmune AstraZeneca Sandoz Novartis GlyFi+ IsMed+ Merck Bioventures Merck Strategy alliances or subsidiaries Company
Chinese Traditional Medicine in Taiwan Western Principle Or new system in Asia?
Success Rates and Time to Market across Therapeutic Areas Source: PharmaPredict.
Source: LES royalty report on the pharmaceutical industry Licensing Strategy in Biotech
Biocluster in Taiwan Taiwan tops the World in the “State Of Cluster Development” For 3 consecutive years (WEF, 2006~2009) NanKang Biotech Park HsinChu Science Park HsinChu Biomedical Science Park Central Taiwan Science Park Southern Taiwan Science Park PingDong Agriculture Science Park Deep Ocean Biotech Park YiLan Biomedical Park
Value Creation in Biotech Industry Value-generation by incubation Patents Commercialization Networking Input Process Output Scientist advisor Market position SIC program, RPC plan, STB program Facilities Experts Regulatory Adm. Licensing Strategy Sources <ul><li>R&D Institutes </li></ul><ul><li>University </li></ul><ul><li>(OTL) </li></ul><ul><li>Industry </li></ul>Clinical Trial Completion Decrease operation risk Diffusion of Management Know-how Milestone set-up Management
Summary <ul><li>Licensing ( License-in, License-out, M&A, Collaboration ) </li></ul><ul><li>Patents (Freedom to operate) </li></ul><ul><li>Contract (design of upfront, milestone payment, royalties) </li></ul><ul><li>Market right (co-development, marketing, sales, regional rights) </li></ul><ul><li>Product Life Cycle ( PDM, PLM ) </li></ul><ul><li>Strategy alliance </li></ul><ul><li>FDA policy and government law </li></ul><ul><li>Regulatory administration 、 Insurance and reimbursement </li></ul><ul><li>Risk analysis (Global economics 、 Business cycle 、 Sensitive analysis ） </li></ul>
The Power of Social Networking in Medicine Source: PatientsLikeMe profile from Nature Biotech, Oct., 2009.
Hospital Mobile Phone Operators Cooperation Manufacturers of medical Device Promotion Business Model Wireless Body Network BD Phillips MicroLife Module sales Networking NTU hospital, Stanford Hospital &Clinics Strategy alliance & Clinical trial Chunghwa Telecom China Mobile
Cancer Progression Cancer Metastasis is responsible for the majority of mortality (>90% for Breast Cancer)
Circulating Tumor Cell <ul><li>Application: </li></ul><ul><ul><li>Survival prognosis </li></ul></ul><ul><ul><li>Monitors metastasis </li></ul></ul><ul><ul><li>Detects recurrence </li></ul></ul><ul><ul><li>Detects targets without biopsy. </li></ul></ul><ul><li>Benefits: </li></ul><ul><li>Noninvasive, more accurate disease assessment. </li></ul><ul><li>Rational selection and early feedback of chemotherapy. </li></ul><ul><li>Works for the major cancers. </li></ul><ul><li>146 clinical trials involving CTC. </li></ul><ul><li>Only 1 company received FDA approval. </li></ul>07/07/11 YFY Group Primary Tumo r Circulating Tumor Cells (CTCs) Blood Vessel
Blood vessel Primary tumor Circulating Tumor Cells in Blood Neutrophil: 50-70% Eosinophil: ~ 5% Basophil: ~ 1% Lymphocyte: 25-35% Monocypte: ~ 5% Red Blood Cells: ~ 1% In 1 mL of Blood: ~ 5 Million White Blood Cells ~ 5 Billion RBCs Veridex Test (7.5 mL):
MiCareo Solution RheoCatch™ Rarefind™ With eDAR <ul><li>3-Color Verification of CTCs (EpCAM+/CK+/CD45-). </li></ul><ul><li>Ultrafast Screening and Single-Molecule Sensitivity. </li></ul><ul><li>Detects 100x more CTCs than FDA-approved method. </li></ul>RareBind™ Reagent Kit RareCatch™ Chip
The Regional Perspectives of Taiwan’s Biotech <ul><li>The characteristics of the Bio-related industry in </li></ul><ul><li>Asia regions ： </li></ul><ul><li>Singapore ： Tax-free, Infrastructures, Talents </li></ul><ul><li>Korea ： Group development, government </li></ul><ul><li>support </li></ul><ul><li>China ： Big market, low labor cost </li></ul><ul><li>Japan : Basic research, closed market </li></ul><ul><li>Taiwan : OEM&ODM, basic research in </li></ul><ul><li>biotech </li></ul>
Future Perspectives <ul><li>Close collaboration with big pharma. </li></ul><ul><li>a. joint venture b. strategic alliances </li></ul><ul><li>Hire more scientific entrepreneurs. </li></ul><ul><li>Define Taiwan’s advantages in Biotech Industry </li></ul><ul><li> medical device or pharmaceuticals ？ </li></ul><ul><li>Highly focus on our strengths constrained with the limited capital and market scale. </li></ul><ul><li>To establish a health investment environment, and </li></ul><ul><li>attract the private investors around the world. </li></ul>